MEP42008A - N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate - Google Patents

N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Info

Publication number
MEP42008A
MEP42008A MEP-420/08A MEP42008A MEP42008A ME P42008 A MEP42008 A ME P42008A ME P42008 A MEP42008 A ME P42008A ME P42008 A MEP42008 A ME P42008A
Authority
ME
Montenegro
Prior art keywords
methoxyethoxy
bis
ethynylphenylamino
monohydrate
quinazolinamine mesylate
Prior art date
Application number
MEP-420/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Douglas John Meldrum Allen
Timothy Norris
Jeffrey William Raggon
Dinos Paul Santafianos
Ravi Mysore Shanker
Original Assignee
Osi Farmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Farmaceuticals Inc filed Critical Osi Farmaceuticals Inc
Publication of MEP42008A publication Critical patent/MEP42008A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-420/08A 1998-04-29 1999-04-08 N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate MEP42008A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29
PCT/IB1999/000612 WO1999055683A1 (en) 1998-04-29 1999-04-08 N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Publications (1)

Publication Number Publication Date
MEP42008A true MEP42008A (en) 2011-02-10

Family

ID=22178359

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-420/08A MEP42008A (en) 1998-04-29 1999-04-08 N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Country Status (42)

Country Link
EP (1) EP1076652B1 (xx)
JP (1) JP4652569B2 (xx)
KR (1) KR100668412B1 (xx)
CN (2) CN1298396A (xx)
AP (1) AP1252A (xx)
AR (1) AR018201A1 (xx)
AT (1) ATE295839T1 (xx)
AU (1) AU759691C (xx)
BR (1) BR9910025A (xx)
CA (1) CA2330447C (xx)
CO (1) CO5060467A1 (xx)
CZ (1) CZ298230B6 (xx)
DE (1) DE69925366T2 (xx)
DZ (1) DZ2777A1 (xx)
EA (1) EA002836B1 (xx)
EG (1) EG24000A (xx)
ES (1) ES2238825T3 (xx)
GT (1) GT199900063A (xx)
HK (1) HK1037180A1 (xx)
HN (1) HN1999000057A (xx)
HU (1) HU227569B1 (xx)
ID (1) ID27198A (xx)
IL (1) IL139172A0 (xx)
MA (1) MA26624A1 (xx)
ME (1) MEP42008A (xx)
MX (1) MXPA00010610A (xx)
MY (1) MY136033A (xx)
NO (1) NO317301B1 (xx)
NZ (1) NZ508154A (xx)
OA (1) OA11769A (xx)
PA (1) PA8471001A1 (xx)
PE (1) PE20000441A1 (xx)
PL (1) PL196940B1 (xx)
RS (1) RS50081B (xx)
SA (1) SA99200216B1 (xx)
TN (1) TNSN99079A1 (xx)
TR (1) TR200003166T2 (xx)
TW (1) TWI248437B (xx)
UA (1) UA60363C2 (xx)
UY (1) UY26099A1 (xx)
WO (1) WO1999055683A1 (xx)
ZA (1) ZA992972B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
MXPA05012939A (es) 2003-05-30 2006-05-17 Astrazeneca Uk Ltd Procedimiento.
PL1680426T3 (pl) 2003-06-10 2008-02-29 Hoffmann La Roche Pochodne 1,3,4-triazafenalenu i 1,3,4,6-tetraazafenalenu
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
BRPI0510717B8 (pt) 2004-05-06 2021-05-25 Bioresponse Llc uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr)
CA2593084C (en) 2004-12-30 2014-03-18 Bioresponse, Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
EP2054393A1 (en) 2006-07-28 2009-05-06 Synthon B.V. Crystalline erlotinib
WO2008057253A2 (en) 2006-10-27 2008-05-15 Bioresponse, L.L.C. Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
US8642758B2 (en) * 2007-04-04 2014-02-04 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
ES2492645T3 (es) 2007-07-11 2014-09-10 Hetero Drugs Limited Un procedimiento mejorado para la preparación de hidrocloruro de erlotinib
US20100136116A1 (en) 2007-08-17 2010-06-03 Hetero Drugs Limited Novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
PT817775E (pt) * 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
MA26624A1 (fr) 2004-12-20
TR200003166T2 (tr) 2001-02-21
CZ20003974A3 (en) 2001-05-16
EG24000A (en) 2008-03-19
MY136033A (en) 2008-07-31
EP1076652A1 (en) 2001-02-21
EA002836B1 (ru) 2002-10-31
AU759691C (en) 2004-04-29
HUP0101818A3 (en) 2002-05-28
KR100668412B1 (ko) 2007-01-12
NO20005453D0 (no) 2000-10-27
CN101219999A (zh) 2008-07-16
BR9910025A (pt) 2000-12-26
AR018201A1 (es) 2001-10-31
DE69925366D1 (de) 2005-06-23
TNSN99079A1 (fr) 2005-11-10
UA60363C2 (uk) 2003-10-15
CA2330447A1 (en) 1999-11-04
PL196940B1 (pl) 2008-02-29
EP1076652B1 (en) 2005-05-18
SA99200216B1 (ar) 2006-06-04
ES2238825T3 (es) 2005-09-01
OA11769A (en) 2005-07-25
UY26099A1 (es) 2001-12-28
YU66100A (sh) 2003-07-07
IL139172A0 (en) 2001-11-25
HUP0101818A1 (hu) 2002-03-28
GT199900063A (es) 2000-10-20
PL343766A1 (en) 2001-09-10
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
JP4652569B2 (ja) 2011-03-16
ID27198A (id) 2001-03-08
HK1037180A1 (en) 2002-02-01
CO5060467A1 (es) 2001-07-30
AP9901523A0 (en) 1999-06-30
CN1298396A (zh) 2001-06-06
AU2850999A (en) 1999-11-16
ZA992972B (en) 2000-10-30
KR20010078710A (ko) 2001-08-21
NZ508154A (en) 2003-07-25
CA2330447C (en) 2009-06-30
MXPA00010610A (es) 2002-07-02
EA200001112A1 (ru) 2001-04-23
AU759691B2 (en) 2003-04-17
AP1252A (en) 2004-02-25
HN1999000057A (es) 1999-09-29
WO1999055683A1 (en) 1999-11-04
PE20000441A1 (es) 2000-05-23
RS50081B (sr) 2009-01-22
JP2002513009A (ja) 2002-05-08
NO317301B1 (no) 2004-10-04
ATE295839T1 (de) 2005-06-15
TWI248437B (en) 2006-02-01
NO20005453L (no) 2000-12-20
CZ298230B6 (cs) 2007-08-01
PA8471001A1 (es) 2000-09-29
HU227569B1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
MEP42008A (en) N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
MY129348A (en) Stable polymorph of n-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4- quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
UY27742A1 (es) Derivados de quinazolina
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
MEP25408A (en) Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
PT1274687E (pt) Derivados de 1,2,3,4-tetra-hidroisoquinolina
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
NO20034230D0 (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
DK1115701T3 (da) Arylsulfonanilidurinstoffer
SE0102315D0 (sv) Compounds
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
CO5601019A2 (es) Polimorfo del clohidrato de la [6,7-bis(2-metoxi-etoxi)-quinazolin-4-il]-(3-etinil-fenil) amina
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
BR0209440A (pt) Sulfonamidas
UY28519A1 (es) Derivados de quinazolina
DE69911023D1 (de) Antagonisten des gonadotropin freisetzenden hormons
HUP0300848A2 (hu) Kamptotecint és egy pirimidinszármazékot tartalmazó készítmény rák kezelésére
NO20030772D0 (no) Fremgangsmåte til fremstilling av vannfritt azitromycin
PT1060175E (pt) Inibidores de triptase
UY26426A1 (es) Nuevos compuestos
ATE279923T1 (de) Urotensin-ii rezeptorantagonisten
YU87501A (sh) Farmaceutski kompleksi
PA8592501A1 (es) Complejos de e-2-metoxi-n-(3-{4-[3-metil-4(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil)acetamida, su procedimiento de produccion y uso
PT1411956E (pt) Utilizacao de polissacaridos sobre-sulfatados como inibidores de vih